Tempus AI, Inc. $TEM Shares Acquired by Krane Funds Advisors LLC

Krane Funds Advisors LLC lifted its holdings in shares of Tempus AI, Inc. (NASDAQ:TEM) by 218.2% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 28,230 shares of the company’s stock after buying an additional 19,358 shares during the period. Tempus AI accounts for approximately 0.1% of Krane Funds Advisors LLC’s holdings, making the stock its 28th biggest position. Krane Funds Advisors LLC’s holdings in Tempus AI were worth $2,427,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Global Retirement Partners LLC boosted its stake in Tempus AI by 29.5% in the third quarter. Global Retirement Partners LLC now owns 733 shares of the company’s stock valued at $59,000 after acquiring an additional 167 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Tempus AI by 0.7% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 33,757 shares of the company’s stock worth $2,145,000 after purchasing an additional 226 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its position in Tempus AI by 2.6% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 9,929 shares of the company’s stock valued at $801,000 after purchasing an additional 248 shares during the period. PNC Financial Services Group Inc. boosted its position in Tempus AI by 6.1% during the 2nd quarter. PNC Financial Services Group Inc. now owns 5,003 shares of the company’s stock valued at $318,000 after purchasing an additional 287 shares during the period. Finally, PFG Investments LLC grew its stake in Tempus AI by 8.5% during the 3rd quarter. PFG Investments LLC now owns 3,830 shares of the company’s stock worth $309,000 after buying an additional 300 shares during the last quarter. Institutional investors and hedge funds own 24.22% of the company’s stock.

Insiders Place Their Bets

In other Tempus AI news, CAO Ryan M. Bartolucci sold 2,902 shares of the company’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $59.05, for a total value of $171,363.10. Following the transaction, the chief accounting officer owned 41,159 shares of the company’s stock, valued at approximately $2,430,438.95. This represents a 6.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Ryan Fukushima sold 9,592 shares of the stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $59.05, for a total value of $566,407.60. Following the sale, the chief executive officer owned 694,354 shares of the company’s stock, valued at $41,001,603.70. This trade represents a 1.36% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 596,035 shares of company stock worth $37,505,125. Company insiders own 26.27% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on TEM shares. Mizuho began coverage on Tempus AI in a research note on Thursday. They issued an “outperform” rating and a $100.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Tempus AI in a research report on Thursday, January 22nd. JPMorgan Chase & Co. cut their price objective on shares of Tempus AI from $85.00 to $80.00 and set a “neutral” rating on the stock in a research report on Monday, December 15th. Morgan Stanley boosted their target price on shares of Tempus AI from $80.00 to $85.00 and gave the company an “overweight” rating in a research note on Monday, December 1st. Finally, BTIG Research upped their target price on shares of Tempus AI from $96.00 to $105.00 and gave the stock a “buy” rating in a research report on Tuesday, November 25th. Eight analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Tempus AI has a consensus rating of “Hold” and an average price target of $85.92.

Tempus AI Price Performance

Shares of NASDAQ TEM opened at $57.29 on Tuesday. Tempus AI, Inc. has a twelve month low of $36.22 and a twelve month high of $104.32. The company has a current ratio of 3.28, a quick ratio of 3.12 and a debt-to-equity ratio of 2.45. The firm has a 50-day moving average of $62.13 and a two-hundred day moving average of $73.61. The company has a market capitalization of $10.19 billion, a price-to-earnings ratio of -48.14 and a beta of 5.22.

Key Stories Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Launched HRD‑RNA algorithm to detect homologous recombination deficiency and added lung‑cancer screening via a partnership with Median Technologies, expanding Tempus’s diagnostic and screening addressable market; this could help grow commercial revenue and clinical adoption. Tempus AI Expands Cancer Workflow With HRD-RNA Launch And Lung Screening
• Positive Sentiment: Analyst attention increased as Mizuho initiated research coverage on TEM, which can improve visibility and liquidity for the stock; initiation often supports demand if the outlook is constructive. Tempus AI (NASDAQ:TEM) Research Coverage Started at Mizuho
• Positive Sentiment: Coverage and commentary highlight TEM’s imaging push (FDA‑cleared tools and Median partnership) as a growth vector — expanding beyond genomics into radiology can broaden product suites and recurring revenue opportunities. Here’s How Tempus AI Is Tapping the Imagining Space
• Neutral Sentiment: Market is watching upcoming earnings (preview coverage) — results and guidance will likely be a near‑term catalyst; until the report details revenue growth, margin trajectory, or bookings, investor reaction will hinge on execution vs. expectations. What’s Next: Tempus AI’s Earnings Preview
• Negative Sentiment: Large insider sales were reported across multiple executives (CEO, CFO, and EVPs totaling several million dollars of stock sold), which can spook investors and be interpreted as reduced insider confidence or portfolio diversification ahead of earnings. Tempus AI (NASDAQ:TEM) CEO Sells $566,407.60 in Stock CFO Sells $595,460.20 in Stock Insider Selling: EVP Sells $562,445.52 in Stock Insider Selling: EVP Sells $480,844.15 in Stock Tempus AI (NASDAQ:TEM) EVP Sells $660,334.19 in Stock

Tempus AI Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.